Ann: NYR-BI03 Phase Ia Clinical Trial Update 2, page-13

Hi all,

This company has been bought to my attention of late, and I'm doing some research into the company and how the drug is aimed to work.

With that, I have come across this interview taken in November (apologies if this has already been posted), which provides a fantastic ground base understanding of the drug.

I see the company has submitted a submission to under take first in human safety trials, although the Q I have is, is the company looking at utilising this drug on other animals such as the monkey that has a much closer brain relation to humans.

Its also interesting to hear how the drug protects the cells by blocking the calcium channels and iron.

Im currently involved in another company that removes excess iron which shows to cause a conciderable amount of neurological injuries.

Anyways, if anyone is able to provide if the company is looking in monkey studies it would be great to hear from you, I will also reach out to the company.

Further research Qs to myself is, are mice cells similar to human cells, if so, will the hopeful results be considerably different.

Anyways, heres the link, watching intently from the sidelines.

https://stocksdownunder.com/video/nyrada-interview-november-2024/